| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
|
J Clin Oncol
|
2011
|
6.18
|
|
2
|
Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28.
|
Pharmacogenet Genomics
|
2007
|
2.01
|
|
3
|
FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth.
|
Cancer Res
|
2010
|
1.99
|
|
4
|
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.
|
J Thorac Oncol
|
2006
|
1.81
|
|
5
|
Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer.
|
J Clin Oncol
|
2010
|
1.69
|
|
6
|
Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer.
|
Cancer Sci
|
2010
|
1.62
|
|
7
|
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
|
Clin Cancer Res
|
2007
|
1.41
|
|
8
|
Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
|
Clin Cancer Res
|
2011
|
1.41
|
|
9
|
Phase I/II study of radiologic hepatic arterial infusion of fluorouracil plus systemic irinotecan for unresectable hepatic metastases from colorectal cancer: Japan Clinical Oncology Group Trial 0208-DI.
|
J Vasc Interv Radiol
|
2012
|
1.38
|
|
10
|
mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells.
|
Cancer Res
|
2009
|
1.36
|
|
11
|
Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.
|
Gastric Cancer
|
2011
|
1.35
|
|
12
|
Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer.
|
J Gastroenterol
|
2009
|
1.34
|
|
13
|
Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
|
Cancer
|
2011
|
1.27
|
|
14
|
SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion.
|
Int J Cancer
|
2009
|
1.21
|
|
15
|
Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer.
|
Clin Cancer Res
|
2008
|
1.19
|
|
16
|
Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2007
|
1.18
|
|
17
|
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1*28 and/or UGT1A1*6 polymorphisms.
|
Cancer Sci
|
2011
|
1.17
|
|
18
|
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
|
Jpn J Clin Oncol
|
2013
|
1.15
|
|
19
|
Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2009
|
1.13
|
|
20
|
Clinical significance of insulin-like growth factor type 1 receptor and epidermal growth factor receptor in patients with advanced gastric cancer.
|
Oncology
|
2008
|
1.11
|
|
21
|
MET amplification as a potential therapeutic target in gastric cancer.
|
Oncotarget
|
2013
|
1.09
|
|
22
|
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
|
Gastric Cancer
|
2013
|
1.08
|
|
23
|
Palliative radiation therapy for hemorrhage of unresectable gastric cancer: a single institute experience.
|
J Cancer Res Clin Oncol
|
2009
|
1.08
|
|
24
|
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations.
|
Invest New Drugs
|
2014
|
1.03
|
|
25
|
Characteristics and outcomes of patients with advanced gastric cancer who declined to participate in a randomized clinical chemotherapy trial.
|
J Oncol Pract
|
2011
|
1.02
|
|
26
|
Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
1.02
|
|
27
|
Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients.
|
Cancer Chemother Pharmacol
|
2009
|
1.01
|
|
28
|
A retrospective analysis of periodontitis during bevacizumab treatment in metastatic colorectal cancer patients.
|
Int J Clin Oncol
|
2012
|
1.01
|
|
29
|
Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors.
|
Clin Cancer Res
|
2010
|
0.99
|
|
30
|
Small cell carcinoma of the esophagus. Analysis of 14 cases and literature review.
|
Hepatogastroenterology
|
2005
|
0.99
|
|
31
|
A Phase 1 clinical study of temsirolimus (CCI-779) in Japanese patients with advanced solid tumors.
|
Jpn J Clin Oncol
|
2010
|
0.99
|
|
32
|
A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors.
|
Cancer Sci
|
2012
|
0.97
|
|
33
|
Genetic variations and frequencies of major haplotypes in SLCO1B1 encoding the transporter OATP1B1 in Japanese subjects: SLCO1B1*17 is more prevalent than *15.
|
Drug Metab Pharmacokinet
|
2007
|
0.97
|
|
34
|
Genetic variations and haplotype structures of the DPYD gene encoding dihydropyrimidine dehydrogenase in Japanese and their ethnic differences.
|
J Hum Genet
|
2007
|
0.96
|
|
35
|
Pharmacokinetic parameters from 3-Tesla DCE-MRI as surrogate biomarkers of antitumor effects of bevacizumab plus FOLFIRI in colorectal cancer with liver metastasis.
|
Int J Cancer
|
2011
|
0.95
|
|
36
|
Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification.
|
Gastric Cancer
|
2011
|
0.93
|
|
37
|
Phase II study of trastuzumab in combination with S-1 and cisplatin in the first-line treatment of human epidermal growth factor receptor HER2-positive advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2015
|
0.92
|
|
38
|
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2011
|
0.92
|
|
39
|
Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study.
|
Gastric Cancer
|
2012
|
0.92
|
|
40
|
Adipocytokines and squamous cell carcinoma of the esophagus.
|
J Cancer Res Clin Oncol
|
2009
|
0.91
|
|
41
|
Close association of UGT1A9 IVS1+399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese.
|
Drug Metab Dispos
|
2008
|
0.91
|
|
42
|
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors.
|
Cancer Sci
|
2009
|
0.91
|
|
43
|
Phase I and pharmacokinetic study of HER2-targeted rhuMAb 2C4 (Pertuzumab, RO4368451) in Japanese patients with solid tumors.
|
Jpn J Clin Oncol
|
2009
|
0.91
|
|
44
|
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
|
Jpn J Clin Oncol
|
2009
|
0.89
|
|
45
|
SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer.
|
PLoS One
|
2012
|
0.89
|
|
46
|
Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma.
|
Cancer Sci
|
2011
|
0.89
|
|
47
|
Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
|
Gastric Cancer
|
2009
|
0.89
|
|
48
|
KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing.
|
Anticancer Res
|
2013
|
0.89
|
|
49
|
Retrospective analysis of clinical results and predictors of response in chemo-naive patients with advanced gastric cancer treated with S-1, an oral fluoropyrimidine derivative, as single-agent chemotherapy.
|
Gastric Cancer
|
2004
|
0.89
|
|
50
|
Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study.
|
Invest New Drugs
|
2012
|
0.88
|
|
51
|
Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
|
J Cancer Res Clin Oncol
|
2010
|
0.88
|
|
52
|
Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
|
Oncotarget
|
2014
|
0.87
|
|
53
|
Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.
|
Br J Clin Pharmacol
|
2010
|
0.87
|
|
54
|
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
|
Clin Cancer Res
|
2007
|
0.87
|
|
55
|
Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer.
|
Cancer Chemother Pharmacol
|
2011
|
0.87
|
|
56
|
Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells.
|
Cancer Sci
|
2011
|
0.86
|
|
57
|
Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts.
|
Cancer Sci
|
2004
|
0.86
|
|
58
|
Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
|
Cancer Chemother Pharmacol
|
2007
|
0.86
|
|
59
|
Clinicopathological features and prognostic roles of KRAS, BRAF, PIK3CA and NRAS mutations in advanced gastric cancer.
|
BMC Res Notes
|
2014
|
0.85
|
|
60
|
Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate.
|
Cancer Chemother Pharmacol
|
2009
|
0.85
|
|
61
|
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
|
Oncology
|
2008
|
0.85
|
|
62
|
Phase I and pharmacokinetic study of ABI-007, albumin-bound paclitaxel, administered every 3 weeks in Japanese patients with solid tumors.
|
Jpn J Clin Oncol
|
2010
|
0.85
|
|
63
|
Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
|
Gastric Cancer
|
2010
|
0.85
|
|
64
|
Phase II clinical trial of second-line FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: AVASIRI trial.
|
Int J Clin Oncol
|
2011
|
0.84
|
|
65
|
Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.84
|
|
66
|
Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2013
|
0.84
|
|
67
|
Functional analysis of four naturally occurring variants of human constitutive androstane receptor.
|
Mol Genet Metab
|
2005
|
0.83
|
|
68
|
Plasma concentrations of angiogenesis-related molecules in patients with pancreatic cancer.
|
Jpn J Clin Oncol
|
2011
|
0.83
|
|
69
|
Phase I study of oral gemcitabine prodrug (LY2334737) in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2013
|
0.82
|
|
70
|
[FOLFIRI regimen for metastatic or recurrent colorectal cancer].
|
Gan To Kagaku Ryoho
|
2006
|
0.82
|
|
71
|
Genetic variations and haplotypes of ABCC2 encoding MRP2 in a Japanese population.
|
Drug Metab Pharmacokinet
|
2008
|
0.82
|
|
72
|
Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection.
|
Cancer Sci
|
2014
|
0.82
|
|
73
|
EGFR L2 domain mutation is not correlated with resistance to cetuximab in metastatic colorectal cancer patients.
|
J Cancer Res Clin Oncol
|
2013
|
0.82
|
|
74
|
Successful rechallenge for oxaliplatin hypersensitivity reactions in patients with metastatic colorectal cancer.
|
Anticancer Res
|
2012
|
0.82
|
|
75
|
Gene amplification of ribosomal protein S6 kinase-1 and -2 in gastric cancer.
|
Anticancer Res
|
2013
|
0.82
|
|
76
|
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
|
Oncologist
|
2014
|
0.82
|
|
77
|
Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
|
Jpn J Clin Oncol
|
2006
|
0.81
|
|
78
|
Genetic polymorphisms of copper- and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients.
|
Drug Metab Pharmacokinet
|
2009
|
0.81
|
|
79
|
A retrospective study of docetaxel or paclitaxel in patients with advanced or recurrent esophageal squamous cell carcinoma who previously received fluoropyrimidine- and platinum-based chemotherapy.
|
Cancer Chemother Pharmacol
|
2014
|
0.81
|
|
80
|
Phase I, pharmacokinetic, and biological studies of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, administered after meals with solid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.81
|
|
81
|
Clinical application of immunoreactivity of dihydropyrimidine dehydrogenase (DPD) in gastric scirrhous carcinoma treated with S-1, a new DPD inhibitory fluoropyrimidine.
|
Anticancer Res
|
2005
|
0.81
|
|
82
|
Phase I and pharmacokinetic study of TSU-68, a novel multiple receptor tyrosine kinase inhibitor, by twice daily oral administration between meals in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.81
|
|
83
|
Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
|
Int J Clin Oncol
|
2009
|
0.81
|
|
84
|
Efficacy of S-1 plus cisplatin combination chemotherapy in patients with HER2-positive advanced gastric cancer.
|
Int J Clin Oncol
|
2013
|
0.81
|
|
85
|
Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
|
Jpn J Clin Oncol
|
2006
|
0.81
|
|
86
|
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil.
|
Int J Cancer
|
2008
|
0.81
|
|
87
|
A phase 1 and dose-finding study of LY2523355 (litronesib), an Eg5 inhibitor, in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.81
|
|
88
|
Impact of CYP3A4 haplotypes on irinotecan pharmacokinetics in Japanese cancer patients.
|
Cancer Chemother Pharmacol
|
2007
|
0.80
|
|
89
|
Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.
|
BMC Cancer
|
2014
|
0.80
|
|
90
|
An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.80
|
|
91
|
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
|
Int J Clin Oncol
|
2004
|
0.79
|
|
92
|
A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
|
Jpn J Clin Oncol
|
2008
|
0.79
|
|
93
|
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
|
Jpn J Clin Oncol
|
2003
|
0.79
|
|
94
|
Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
|
Anticancer Res
|
2012
|
0.79
|
|
95
|
Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
|
Cancer Res
|
2008
|
0.79
|
|
96
|
Impact of vascular endothelial growth factor receptor 1, 2, and 3 expression on the outcome of patients with gastric cancer.
|
Cancer Sci
|
2009
|
0.79
|
|
97
|
Progression-free survival in first-line chemotherapy is a prognostic factor in second-line chemotherapy in patients with advanced gastric cancer.
|
J Cancer Res Clin Oncol
|
2010
|
0.79
|
|
98
|
A feasibility study of outpatient chemotherapy with S-1 + cisplatin in patients with advanced gastric cancer.
|
Gastric Cancer
|
2012
|
0.78
|
|
99
|
Weekly paclitaxel as second-line chemotherapy in Japanese patients with advanced gastric cancer.
|
Anticancer Res
|
2013
|
0.78
|
|
100
|
Combination of O6-methylguanine-DNA methyltransferase and thymidylate synthase for the prediction of fluoropyrimidine efficacy.
|
Eur J Cancer
|
2007
|
0.78
|
|
101
|
Phase II study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel as first-line therapy for advanced gastric cancer.
|
Oncology
|
2011
|
0.78
|
|
102
|
[Pharmacokinetics of S-1].
|
Gan To Kagaku Ryoho
|
2006
|
0.78
|
|
103
|
Standard First-Line Chemotherapy for Metastatic Gastric Cancer in Japan Has Met the Global Standard: Evidence From Recent Phase III Trials.
|
Gastrointest Cancer Res
|
2009
|
0.78
|
|
104
|
A phase I study of resminostat in Japanese patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2015
|
0.77
|
|
105
|
[Impact of HER2, EGFR, IGF-1R, and VEGFR expressions on the outcome of chemotherapy for advanced gastric cancer].
|
Gan To Kagaku Ryoho
|
2010
|
0.77
|
|
106
|
Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer.
|
Invest New Drugs
|
2015
|
0.77
|
|
107
|
Genetic polymorphisms of FCGR2A encoding Fcγ receptor IIa in a Japanese population and functional analysis of the L273P variant.
|
Immunogenetics
|
2012
|
0.77
|
|
108
|
Lack of association of proteinuria and clinical outcome in patients treated with bevacizumab for metastatic colorectal cancer.
|
Anticancer Res
|
2013
|
0.77
|
|
109
|
Comparison of advanced adenocarcinomas of esophagogastric junction and distal stomach in Japanese patients.
|
Gastric Cancer
|
2013
|
0.77
|
|
110
|
Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan.
|
Support Care Cancer
|
2003
|
0.76
|
|
111
|
Genetic variation and haplotype structures of the glutathione S-transferase genes GSTA1 and GSTA2 in Japanese colorectal cancer patients.
|
Drug Metab Pharmacokinet
|
2011
|
0.76
|
|
112
|
Systemic chemotherapy for peritoneal disseminated gastric cancer with inadequate oral intake: a retrospective study.
|
Int J Clin Oncol
|
2010
|
0.76
|
|
113
|
Impact of adding cisplatin to S-1 in elderly patients with advanced gastric cancer.
|
J Cancer Res Clin Oncol
|
2013
|
0.76
|
|
114
|
Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer.
|
Int J Clin Oncol
|
2012
|
0.76
|
|
115
|
First-line fluorouracil-based chemotherapy for patients with severe peritoneal disseminated gastric cancer.
|
Gastric Cancer
|
2011
|
0.76
|
|
116
|
Three novel single nucleotide polymorphisms in UGT1A10.
|
Drug Metab Pharmacokinet
|
2002
|
0.75
|
|
117
|
Genetic polymorphisms of FCGRT encoding FcRn in a Japanese population and their functional analysis.
|
Drug Metab Pharmacokinet
|
2010
|
0.75
|
|
118
|
Prognostic significance of thymidylate synthase in patients with metastatic colorectal cancer who receive protracted venous infusions of 5-fluorouracil.
|
Int J Clin Oncol
|
2004
|
0.75
|
|
119
|
Tumor KRAS status predicts responsiveness to panitumumab in Japanese patients with metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2010
|
0.75
|
|
120
|
A phase I study of BMS-690514 in Japanese patients with advanced or metastatic solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.75
|
|
121
|
Prognostic factors for patients with metastatic colorectal cancer receiving protracted venous infusion of 5-FU.
|
Am J Clin Oncol
|
2002
|
0.75
|
|
122
|
Value of KRAS, BRAF, and PIK3CA Mutations and Survival Benefit from Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.
|
Asian Pac J Cancer Prev
|
2016
|
0.75
|
|
123
|
Effect of a 3-hour interval between methotrexate and 5-fluorouracil in the treatment of metastatic colorectal cancer.
|
Jpn J Clin Oncol
|
2002
|
0.75
|
|
124
|
A novel multimodal approach for locally advanced rectal cancer involving the pelvic sidewall.
|
Hepatogastroenterology
|
2011
|
0.75
|
|
125
|
[Neoadjuvant therapy for esophageal cancer - indication and efficacy].
|
Gan To Kagaku Ryoho
|
2007
|
0.75
|
|
126
|
S-1 and irinotecan with or without bevacizumab versus 5-fluorouracil and leucovorin plus oxaliplatin with or without bevacizumab in metastatic colorectal cancer: a pooled analysis of four phase II studies.
|
Cancer Chemother Pharmacol
|
2015
|
0.75
|
|
127
|
[FOLFOX-related hypersensitivity reactions: clinical presentation and management].
|
Nihon Rinsho
|
2011
|
0.75
|
|
128
|
Phase I study of combination therapy with irinotecan, leucovorin, and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for advanced colorectal cancer in Japanese patients.
|
Anticancer Res
|
2014
|
0.75
|
|
129
|
Phase I and pharmacokinetics/pharmacodynamics study of the MEK inhibitor RO4987655 in Japanese patients with advanced solid tumors.
|
Invest New Drugs
|
2015
|
0.75
|
|
130
|
The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
|
Future Oncol
|
2015
|
0.75
|
|
131
|
[Predictive markers for platinum-based chemotherapy].
|
Gan To Kagaku Ryoho
|
2008
|
0.75
|
|
132
|
Patterns of Relapse after Definitive Chemoradiotherapy in Stage II/III (Non-T4) Esophageal Squamous Cell Carcinoma.
|
Oncology
|
2017
|
0.75
|
|
133
|
[Chemotherapy and trastuzumab for HER2 positive gastric cancer].
|
Nihon Rinsho
|
2015
|
0.75
|
|
134
|
Long-term survivor of gastric small cell carcinoma.
|
Hepatogastroenterology
|
2004
|
0.75
|
|
135
|
A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruption.
|
Jpn J Clin Oncol
|
2012
|
0.75
|
|
136
|
The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
|
Anticancer Res
|
2014
|
0.75
|
|
137
|
Amrubicin in patients with platinum-refractory metastatic neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the gastrointestinal tract.
|
Anticancer Drugs
|
2016
|
0.75
|